NCT03562754View on ClinicalTrials.gov

Control Trial of Intermittent Hemodialysis With Regional Citrate VS Priming Heparin With Predilution in Patients at Risk of Bleeding

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Hemodialysis
Interventions
PROCEDURE

reduced systemic heparin anticoagulation

receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate

PROCEDURE

Regional Citrate Anticoagulation

intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer

Trial Locations (1)

30029

CHU Nimes, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT03562754 - Control Trial of Intermittent Hemodialysis With Regional Citrate VS Priming Heparin With Predilution in Patients at Risk of Bleeding | Biotech Hunter | Biotech Hunter